

B³ 12. (Amended) The method of claim 8 wherein a dose of the PYY or PYY agonist sufficient to achieve a peak plasma level equivalent to that achieved by an infusion of PYY or PYY agonist of about 300 $\mu\text{g/kg/day}$ to about 1000 $\mu\text{g/kg/day}$ is administered.

B⁴ 23. (Amended) A method for treating conditions or disorders which can be alleviated by reducing nutrient availability in a subject comprising administering to said subject an amount of a PYY or a PYY agonist effective to reduce caloric efficiency.

B⁵ 31. (Amended) The method of claim 23 wherein about 300 μg to about 1 mg of the PYY or PYY agonist is administered per day in single or divided doses.

32. (Amended) The method of claim 23 wherein a dose of the PYY or PYY agonist sufficient to achieve a peak plasma level equivalent to that achieved by a continuous infusion of PYY or PYY agonist of about 300 $\mu\text{g/kg/day}$ to about 1000 $\mu\text{g/kg/day}$ is administered.

REMARKS

The Office Action mailed November 15, 2002 has been reviewed, and in view of the foregoing amendment and following remarks, reconsideration and allowance of all of the claims under consideration in the application are respectfully requested. Claims 1-33 are currently pending, of which claims 1, 4-12, 23, 29, and 31-33 are under consideration. Claims 1, 6, 7, 8, 11, 12, 23, 31, and 32 have been amended by way of the present amendment. Support for these amendments can be found throughout the specification, for example, but without limitation, Example 7.

I. Rejection of the Claims under 35 U.S.C. § 103(a)

Claims 1, 4-12, 23, 29, and 31-33 stand rejected under 35 U.S.C. § 103(a) as allegedly being unpatentable over Malaisse-Lagae *et al.* in view of Yoshinaga *et al.*, Allen *et al.*, and Ueno *et al.* This rejection is respectfully traversed for at least the reasons which follow.

The Examiner asserts that Malaisse-Lagae *et al.* demonstrate decreased food intake and reduced weight gain in *ob/ob* mice following administration of pancreatic polypeptide (PP); that Yoshinaga *et al.* disclose the structural characteristics of Peptide YY (PYY); that Allen *et al.* demonstrate the effect of PYY on gastric emptying of glucose; and finally, that Ueno *et al.* disclose that mice which over-express PP show a decreased secretion of pancreatic exocrine.